
Opinion|Videos|January 21, 2025
Discussing Treatment Options for BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
A panelist discusses how treatment decisions involve balancing clinical efficacy with financial considerations, noting that patients often prefer treatments with fewer office visits and minimal lifestyle disruption when presented with multiple effective options.
Advertisement
Episodes in this series

- What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies?
- With all the available treatments on market, what are your patient preferences when it comes to treatment experiences?
- With all the available treatments on market, what are your patient preferences when it comes to treatment experiences?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
3
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5











